GETI.B

192.4

+0.58%↑

VITR

138.5

+0.65%↑

ATT

69.1

+0.88%↑

ARJOB

33.5

+0.84%↑

MSON.B

7.72

-0.77%↓

GETI.B

192.4

+0.58%↑

VITR

138.5

+0.65%↑

ATT

69.1

+0.88%↑

ARJOB

33.5

+0.84%↑

MSON.B

7.72

-0.77%↓

GETI.B

192.4

+0.58%↑

VITR

138.5

+0.65%↑

ATT

69.1

+0.88%↑

ARJOB

33.5

+0.84%↑

MSON.B

7.72

-0.77%↓

GETI.B

192.4

+0.58%↑

VITR

138.5

+0.65%↑

ATT

69.1

+0.88%↑

ARJOB

33.5

+0.84%↑

MSON.B

7.72

-0.77%↓

GETI.B

192.4

+0.58%↑

VITR

138.5

+0.65%↑

ATT

69.1

+0.88%↑

ARJOB

33.5

+0.84%↑

MSON.B

7.72

-0.77%↓

Search

Camurus AB

Gesloten

665 -0.89

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

657

Max

685.5

Belangrijke statistieken

By Trading Economics

Inkomsten

292M

531M

Verkoop

117M

676M

K/W

Sectorgemiddelde

55.967

40.048

EPS

4.08

Winstmarge

78.598

Werknemers

267

EBITDA

71M

261M

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-416M

40B

Vorige openingsprijs

665.89

Vorige sluitingsprijs

665

Camurus AB Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 aug 2025, 23:11 UTC

Winsten

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

5 aug 2025, 22:45 UTC

Winsten

Australia's REA Hikes Dividend as Annual Profit Rises 23%

5 aug 2025, 22:39 UTC

Winsten

Great-West Lifeco Logs Lower 2Q Profit

5 aug 2025, 21:32 UTC

Winsten

Coupang Posts Higher 2Q Sales Due to Customer Growth

6 aug 2025, 00:00 UTC

Acquisities, Fusies, Overnames

NFL to Take 10% Stake in Disney's ESPN -- WSJ

6 aug 2025, 00:00 UTC

Acquisities, Fusies, Overnames

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

6 aug 2025, 00:00 UTC

Acquisities, Fusies, Overnames

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

6 aug 2025, 00:00 UTC

Acquisities, Fusies, Overnames

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

5 aug 2025, 23:48 UTC

Marktinformatie

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

5 aug 2025, 23:40 UTC

Marktinformatie

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

5 aug 2025, 23:19 UTC

Marktinformatie

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

5 aug 2025, 23:03 UTC

Marktinformatie
Winsten

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

5 aug 2025, 22:22 UTC

Winsten

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

5 aug 2025, 22:21 UTC

Winsten

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

5 aug 2025, 22:20 UTC

Winsten

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

5 aug 2025, 22:18 UTC

Winsten

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

5 aug 2025, 22:17 UTC

Winsten

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

5 aug 2025, 22:17 UTC

Winsten

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

5 aug 2025, 22:16 UTC

Winsten

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

5 aug 2025, 22:16 UTC

Winsten

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

5 aug 2025, 22:15 UTC

Winsten

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

5 aug 2025, 22:13 UTC

Winsten

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

5 aug 2025, 22:13 UTC

Winsten

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

5 aug 2025, 22:12 UTC

Winsten

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

5 aug 2025, 22:12 UTC

Winsten

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

5 aug 2025, 21:58 UTC

Winsten

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5 aug 2025, 21:30 UTC

Winsten

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

5 aug 2025, 21:26 UTC

Winsten

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

5 aug 2025, 21:23 UTC

Winsten

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

5 aug 2025, 21:17 UTC

Winsten

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Peer Vergelijking

Prijswijziging

Camurus AB Prognose

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.